TY - JOUR
T1 - Needs for information and reasons for (non-)adherence in chronic myeloid leukaemia
T2 - be aware of social activities disturbing daily routines
AU - Boons, Christel C L M
AU - Harbers, Lorette
AU - Timmers, Lonneke
AU - de Jong, Jan
AU - Swart, Eleonora L
AU - Hendrikse, N Harry
AU - Janssen, Jeroen J W M
AU - Hugtenburg, Jacqueline G
PY - 2018/11
Y1 - 2018/11
N2 - OBJECTIVES: To obtain insight into patients' reasons for medication (non-)adherence in chronic myeloid leukaemia (CML) and needs and wishes regarding information and communication.METHODS: A mixed-method study on the basis of a questionnaire and semi-structured interviews. The CML patient advocacy group asked patients to participate.RESULTS: Sixty-one patients (54±12 years, 43% male) using imatinib, dasatinib, or nilotinib participated. Fifteen patients (25%) reported to miss an intake at least once a month. Most were not worried about missing an intake and did not discuss missed intakes with their healthcare provider (HCP). Social activities disturbing daily routines and the wish to avoid side-effects resulted in non-adherence. Patients wanted extensive and understandable information provided timely on all aspects of CML treatment, in particular on side-effects, and a more supportive HCP attitude.CONCLUSIONS: Non-adherence to CML medication does not cause concern in all patients and is not discussed pro-actively. HCP have a clear role in supporting medication adherence in CML and must be aware that social activities disturbing daily routines contribute to non-adherence. HCP should discuss (non-)adherence in a direct manner, motivate patients to play an active role in managing their medication, and timely provide extensive and understandable information on all aspects of CML. This article is protected by copyright. All rights reserved.
AB - OBJECTIVES: To obtain insight into patients' reasons for medication (non-)adherence in chronic myeloid leukaemia (CML) and needs and wishes regarding information and communication.METHODS: A mixed-method study on the basis of a questionnaire and semi-structured interviews. The CML patient advocacy group asked patients to participate.RESULTS: Sixty-one patients (54±12 years, 43% male) using imatinib, dasatinib, or nilotinib participated. Fifteen patients (25%) reported to miss an intake at least once a month. Most were not worried about missing an intake and did not discuss missed intakes with their healthcare provider (HCP). Social activities disturbing daily routines and the wish to avoid side-effects resulted in non-adherence. Patients wanted extensive and understandable information provided timely on all aspects of CML treatment, in particular on side-effects, and a more supportive HCP attitude.CONCLUSIONS: Non-adherence to CML medication does not cause concern in all patients and is not discussed pro-actively. HCP have a clear role in supporting medication adherence in CML and must be aware that social activities disturbing daily routines contribute to non-adherence. HCP should discuss (non-)adherence in a direct manner, motivate patients to play an active role in managing their medication, and timely provide extensive and understandable information on all aspects of CML. This article is protected by copyright. All rights reserved.
KW - chronic myeloid leukaemia
KW - medication adherence
KW - medication information
KW - patients' experiences
KW - qualitative research
KW - tyrosine kinase inhibitors
U2 - https://doi.org/10.1111/ejh.13155
DO - https://doi.org/10.1111/ejh.13155
M3 - Article
C2 - 30058149
SN - 0902-4441
VL - 101
SP - 643
EP - 653
JO - European journal of haematology
JF - European journal of haematology
IS - 5
ER -